A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Chenna Keshava Reddy Sannala und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pumas-AI, Inc, Dover, DE, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Gonadotropin-Releasing Hormone, Models, Biological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Teverelix drug product (DP) is a parenteral gonadotropin‐releasing hormone (GnRH) antagonist that has been successfully tested in phase 2 trials for hormone‐sensitive advanced prostate cancer (APC) and benign prostatic hyperplasia (BPH). In previous APC trials, teverelix DP was administered as intramuscular (IM) and subcutaneous (SC) injections, using a loading dose and (in a single trial) a maintenance dose. Our objective was to derive an optimal dosing regimen for phase 3 clinical development, using a pharmacometrics modeling approach. Data from 9 phase 2 studies (229 patients) was utilized to develop a population pharmacokinetic (PK) model that described the concentration profile accommodating both IM and SC routes of administration. A 2‐compartment model with sequential first‐order absorption (slow and fast) and lag times best described the PK profiles of teverelix following SC and IM administration. An indirect response model with inhibition of production rate was fit to describe testosterone (T) concentrations based on physiological relevance. The final population PK–pharmacodynamic model was used to conduct simulations of various candidate dosing regimens to select the optimal dosing regimen to achieve clinical castration (T < 0.5 ng/mL by day 28) and to sustain clinical castration for 26 weeks. Model simulation showed that a loading dose of 360 mg SC and 180 mg IM with a maintenance dose of 360 mg SC 6‐weekly (Q6W) starting at day 28 can achieve a ≥95% castration rate up to 52 weeks. This dose regimen was selected for phase 3 clinical development, which includes cardiovascular safety assessment in comparison to a GnRH agonist.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pumas-AI, Inc, Dover, DE, USA.
- Antev Ltd, London, UK.
- Vivpro Corp, Landsdale, PA, USA.
- Carolina Urologic Research Center, Myrtle Beach, SC, USA.
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Rush University Medical Center, Chicago, IL, USA.
Zitieren
APA
Sannala, C. K. R., MacLean, C., Larsen, F., van Os, S., Jadhav, P., Shore, N., Morgans, A. K., Okwuosa, T., & Gobburu, J. (2024). A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1415
Vancouver
Sannala CKR, MacLean C, Larsen F, van Os S, Jadhav P, Shore N, et al. A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1415
BibTeX
@article{Sannala2024,
author = {Sannala, Chenna Keshava Reddy and MacLean, Carol and Larsen, Finn and van Os, Steve and Jadhav, Pravin and Shore, Neal and Morgans, Alicia K and Okwuosa, Tochukwu and Gobburu, Joga},
title = {A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1415}
}
EUVIMED